Breast Cancer Clinical Trial
Study of 2 Ribociclib Doses in Combination With Aromatase Inhibitors in Women With HR+, HER2- Advanced Breast Cancer
Summary
QT interval prolongation and neutropenia are considered to be important identified risks for ribociclib. The approved dosing regimen of ribociclib is 600 mg daily (QD) on a 3 weeks on/1 week off schedule.
The purpose of the study is to explore whether a reduced dosing regimen of 400 mg ribociclib orally QD 3 weeks on/1 week off may decrease the risk of QTc prolongation without compromising the efficacy of ribociclib in combination with an NSAI in pre- and postmenopausal women with HR-positive, HER2-negative aBC who have received no prior therapy for advanced disease. The risks of other AEs of special interest, such as neutropenia and hepatobiliary toxicity will be evaluated in this study as well.
Approximately 350 patients will be randomly assigned to one of the below treatment arms in a 1:1 ratio: Experimental arm (Arm 1) - Ribociclib 400 mg QD 3 weeks on/1 week off + NSAI (+ goserelin in premenopausal women): 175 patients Control arm (Arm 2) - Ribociclib 600 mg QD 3 weeks on/1 week off + NSAI (+ goserelin in premenopausal women): 175 patients Randomization will be stratified by the presence of lung and/or liver metastases (yes versus no).
Eligibility Criteria
Key Inclusion criteria:
Patient has advanced (loco-regionally recurrent or metastatic) breast cancer not amenable to curative therapy.
Patient has a histologically and/or cytologically confirmed diagnosis of ER-positive and/or PgR-positive breast cancer based on the most recently analyzed tissue sample, and all tested by local laboratory.
Patient has HER2-negative breast cancer defined as a negative in situ hybridization test or an IHC status of 0, 1+ or 2+. If IHC is 2+, a negative in situ hybridization (FISH, CISH, or SISH) test is required by local laboratory testing and based on the most recently analyzed tissue sample.
Patient must have measurable disease, i.e., at least one measurable lesion according to RECIST version 1.1. (a lesion in a previously irradiated site may only be counted as a target lesion if there is clear evidence of progression since the irradiation).
Patient has an Eastern Cooperative Oncology Group (ECOG) performance status 0 or 1.
Standard 12-lead ECG values defined as the mean of the triplicate ECGs and assessed by the central laboratory:
QTcF interval at screening < 450 ms (QT interval using Fridericia's correction)
Mean resting heart rate 50 to 90 bpm (determined from the ECG)
Women of childbearing potential (CBP), defined as all women physiologically capable of becoming pregnant, must have confirmed negative serum pregnancy test (for β-hCG) within 14 days prior to randomization.
Women of CBP must be willing to use highly effective methods of contraception.
Key Exclusion Criteria:
Patient with symptomatic visceral disease or any disease burden that makes the patient ineligible for endocrine therapy per the investigator's judgment.
Patient who received any prior systemic anti-cancer therapy(including endocrine therapy, chemotherapy, prior CDK4/6 inhibitors) for aBC. Patients who received neo-/adjuvant therapy for breast cancer are eligible.
Patient is concurrently using other anti-cancer therapy.
Patient has had major surgery within 14 days prior to starting study drug or has not recovered from major toxicities.
Patient has received extended-field radiotherapy ≤ 4 weeks or limited field radiotherapy ≤ 2 weeks prior to randomization, and has not recovered to grade 1 or better from related side effects of such therapy (with the exception of alopecia or other toxicities not considered a safety risk for the patient at investigator's discretion). Patients in whom ≥ 25% of the bone marrow has been previously irradiated are also excluded.
Patient has a concurrent malignancy or malignancy within 3 years of the randomization date, with the exception of adequately treated basal or squamous cell skin carcinoma, or curatively resected cervical carcinoma in situ.
Patients with central nervous system (CNS) involvement unless they meet specific stability criteria.
Patient has clinically significant, uncontrolled heart disease and/or cardiac repolarization abnormality.
Patient is currently receiving or has received systemic corticosteroids ≤ 2 weeks prior to starting study drug, and has not fully recovered from side effects of such treatment.
Other protocol-defined Inclusion/Exclusion may apply.
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There are 88 Locations for this study
Mobile Alabama, 36608, United States
Greenbrae California, 94904, United States
Longmont Colorado, 80501, United States
Orlando Florida, 32804, United States
Atlanta Georgia, 30322, United States
Baltimore Maryland, 21237, United States
Lincoln Nebraska, 68506, United States
Omaha Nebraska, 68154, United States
Henderson Nevada, 89052, United States
Albany New York, 12208, United States
Bronx New York, 10467, United States
New York New York, 10029, United States
Houston Texas, 77090, United States
McAllen Texas, 78503, United States
Tacoma Washington, 98405, United States
San Juan , J5402, Argentina
Innsbruck , A-602, Austria
Linz , 4010, Austria
Salzburg , 5020, Austria
Vienna , 1090, Austria
Edegem Antwerpen, 2650, Belgium
Namur , 5000, Belgium
Goiania GO, 74605, Brazil
Natal RN, 59075, Brazil
Florianopolis Santa Catarina, 88034, Brazil
Sao Paulo SP, 01317, Brazil
Sao Paulo SP, 04014, Brazil
Sao Jose do Rio Preto , 15090, Brazil
Plovdiv , 4004, Bulgaria
Sofia , 1303, Bulgaria
Sofia , 1756, Bulgaria
Cambridge Ontario, N1R 3, Canada
Valledupar Cesar, 56023, Colombia
Ibague Tolima, 73000, Colombia
Bogota , 11022, Colombia
Bogota , , Colombia
Monteria , 23000, Colombia
San Jose , , Costa Rica
Brno Czech Republic, 656 5, Czechia
Praha 5 , 150 0, Czechia
Helsinki , 00029, Finland
Tampere , FIN-3, Finland
Besancon Cedex , 25030, France
Caen Cedex , 14021, France
Clermont Ferrand , 63011, France
Lyon Cedex 08 , 69373, France
Marseille , 13273, France
Montpellier Cedex 5 , 34298, France
Saint Herblain cedex , 44805, France
Strasbourg , F 670, France
Valenciennes , 59300, France
Langen Hessen, 63225, Germany
Augsburg , 86150, Germany
Berlin , 13581, Germany
Bonn , 53111, Germany
Dresden , 01127, Germany
Dresden , 01307, Germany
Essen , 45136, Germany
Tübingen , 72076, Germany
Weiden , 92637, Germany
Budapest , H 112, Hungary
Debrecen , 4032, Hungary
Szolnok , H-500, Hungary
Raipur Chhattisgarh, 49200, India
Nagpur Maharashtra, 44110, India
Bhubaneshwar Orissa, 75100, India
Delhii , 110 0, India
Mumbai , 400 0, India
Amman , 11941, Jordan
Kaunas LTU, LT 50, Lithuania
Vilnius , LT-08, Lithuania
Trujillo La Libertad, , Peru
San Borja Lima, 41, Peru
San Isidro Lima, 27, Peru
San Miguel Lima, 32, Peru
Lisbon , 1400 , Portugal
Loures , 26745, Portugal
Porto , 4200-, Portugal
Arkhangelsk , 16304, Russian Federation
Moscow , 11112, Russian Federation
Moscow , 11547, Russian Federation
St Petersburg , 19775, Russian Federation
St-Petersburg , 18964, Russian Federation
Cape Town , 7500, South Africa
Johannesburg , 2196, South Africa
Parktown , 2193, South Africa
Stockholm , 112 1, Sweden
Stockholm , SE-11, Sweden
Uppsala , 751 8, Sweden
Bangkok , 10700, Thailand
Chiang Mai , 50200, Thailand
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.